Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

This study (MILESTONE) looks at whether patients with newly diagnosed multiple myeloma (a blood cancer) who achieve a very deep remission can safely delay or avoid a stem cell transplant by monitoring a measure of remaining disease called minimal residual disease (MRD). **You may be eligible if...** - You are 18 or older with newly diagnosed multiple myeloma requiring treatment - You have measurable disease (confirmed by specific lab tests) - You have adequate liver and kidney function - You are potentially eligible for a stem cell transplant per your doctor's assessment - You are willing to follow study requirements including contraception during treatment **You may NOT be eligible if...** - You have POEMS syndrome or Waldenstrom's macroglobulinemia - You have recently had surgery, major radiation, or serious infection - You are pregnant or breastfeeding - You have uncontrolled HIV, hepatitis B, or hepatitis C - You have severe heart disease or a recent heart attack (within 4 months) - You have had a stroke within the past year - You have significant nerve damage (neuropathy grade 3–4) - You have another active cancer (outside of certain limited exceptions) Talk to your doctor to see if this trial is right for you.